Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).
Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).
复制标题
DOI：
10.1016/j.therap.2022.03.005
复制
发表时间：
2022-09
期刊：
影响因子：
2.6
通讯作者：
Solas, Caroline
中科院分区：
文献类型：
--
作者：
Lemaitre, Florian;Gregoire, Matthieu;Monchaud, Caroline;Bouchet, Stephane;Saint-Salvi, Beatrice;Polard, Elisabeth;Benaboud, Sihem;Chouchana, Laurent;Cracowski, Jean-Luc;Drici, Milou-Daniel;Garraffo, Rodolphe;Guilhaumou, Romain;Jonville-Bera, Annie-Pierre;Molimard, Mathieu;Muret, Patric;Peytavin, Gilles;Richard, Vincent;Solas, Caroline
Nirmatrelvir联合ritonavir （PAXLOVID™，辉瑞）是一种靶向3-凝乳胰蛋白酶样半胱氨酸蛋白酶（3c样蛋白酶或Mpro）的抗病毒药物，该酶是严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）病毒周期的关键酶。这种与一种众所周知的药代动力学增强剂的结合导致在选择多药治疗的人群中发生药物-药物相互作用的高风险。这项工作的目的是代表法国国家药理学学会（French society of pharmacology and Therapeutics； SFPT）提供建议，如果nirmatrelvir/ritonavir与常用药物一起使用，则建议最佳和实用的治疗策略，以确保医生的处方安全。六位临床药理学家检索了科学文献，提供了建议的初稿。此后，其他12位临床药理学家验证了这些建议并提出了修改意见。最后的草稿由所有18位参与者进行验证。发布了五项不同的建议：i)禁忌症，ii)“PAXLOVID™不建议与药物一起使用”，iii)“PAXLOVID™是否可能与药物一起使用”，iv)“PAXLOVID™仅在专家建议后才可能使用”和v)“PAXLOVID™无需修改相关治疗”。最终文件包括旨在确保处方的171种药物/治疗类别的建议。在复杂的情况下，建议临床医生联系他们的药理学部门，以获得关于管理与尼马特利韦/利托那韦的药物-药物相互作用的具体建议。这些建议旨在帮助临床医生愿意开尼马特利韦/利托那韦，并防止药物相互作用导致药物不良反应或药效丧失。它们构成初级保健情况的指导方针。当然，一些复杂的情况可能需要专家的建议，在这里，临床药理学家再次站在提供治疗建议的最前沿。
Nirmatrelvir in association with ritonavir (PAXLOVID™, Pfizer) is an antiviral agent targeting the 3-chymotrypsin–like cysteine protease enzyme (3C-like protease or Mpro) which is a key enzyme of the viral cycle of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This combination with a well-known pharmacokinetic enhancer leads to a high risk for drug-drug interactions in a polymedicated elected population for treatment. The aim of this work was to provide recommendations on behalf of the national French society of pharmacology (French Society of Pharmacology and Therapeutics; SFPT), by suggesting optimal and pragmatic therapeutic strategies if nirmatrelvir/ritonavir is to be given together with drugs commonly used, in order to ensure secured physicians’ prescription. Six clinical pharmacologists search the scientific literature to provide a first draft of recommendations. Thereafter, twelve other clinical pharmacologists verified the recommendations and proposed modifications. The final draft was then validated by all 18 participants. Five distinct recommendations were issued: i) contra-indications, ii) “PAXLOVID™ not recommended with the comedication”, iii) “PAXLOVID™ possible whether the comedication is discontinued”, iv) “PAXLOVID™ possible only after an expert advice” and v) “PAXLOVID™ possible without modification of the associated treatment”. The final document comprises recommendations for 171 drugs/therapeutic classes aiming to secure prescription. In complex situations, clinicians are advised to contact their pharmacology department to obtain specific recommendations on the management of drug-drug interactions with nirmatrelvir/ritonavir. These recommendations intend to be a help for clinicians willing to prescribe nirmatrelvir/ritonavir and to prevent drug-drug interactions leading to adverse drug reactions or loss of efficacy. They constitute a guideline for primary care situations. Of course, some complex situations may require expert advices and here, again, clinical pharmacologists are at the forefront in providing therapeutic advice.
登录
查看更多内容
DOI：
10.1056/nejmoa2116846
发表时间：
2022-01-27
期刊：
The New England journal of medicine
影响因子：
--
作者：
Gottlieb RL;Vaca CE;Paredes R;Mera J;Webb BJ;Perez G;Oguchi G;Ryan P;Nielsen BU;Brown M;Hidalgo A;Sachdeva Y;Mittal S;Osiyemi O;Skarbinski J;Juneja K;Hyland RH;Osinusi A;Chen S;Camus G;Abdelghany M;Davies S;Behenna-Renton N;Duff F;Marty FM;Katz MJ;Ginde AA;Brown SM;Schiffer JT;Hill JA;GS-US-540-9012 (PINETREE) Investigators
通讯作者：
GS-US-540-9012 (PINETREE) Investigators
影响因子：
3.4
作者：
Ouellet, D;Hsu, A;Granneman, GR
通讯作者：
Granneman, GR
影响因子：
3.4
作者：
Grimm, SW;Richtand, NM;Reele, SB
通讯作者：
Reele, SB
DOI：
10.1056/nejmoa2118542
发表时间：
2022-04-14
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hammond J;Leister-Tebbe H;Gardner A;Abreu P;Bao W;Wisemandle W;Baniecki M;Hendrick VM;Damle B;Simón-Campos A;Pypstra R;Rusnak JM;EPIC-HR Investigators
通讯作者：
EPIC-HR Investigators
影响因子：
158.5
作者：
Gupta, Anil;Gonzalez-Rojas, Yaneicy;Shapiro, Adrienne E.
通讯作者：
Shapiro, Adrienne E.